About 50% of women have dense or very dense breasts. With a mammogram, the denser the breast tissue, the lighter the tissue appears on an image. This can make it more difficult to detect abnormal masses, which also appear white on the image.³
Information for physicians and healthcare professionals
As a physician, you know that with a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, a significant portion of women have reduced opportunity for an early, life-saving diagnosis.
That’s why we developed Syantra DX™ Breast Cancer.
A new tool for breast cancer screening
One in eight women will develop breast cancer in her lifetime.¹
Although many of those women will be detected through screening efforts, a large number of them will not. In fact, 18 percent of breast cancer diagnoses in Canada are women below 50-years old,² but in most provinces, routine screening by mammogram isn’t recommended until after a woman turns 50-years-old (for women without symptoms, of average risk).
To make matters more challenging, screening by mammography alone does not detect all cancers at an early stage, particularly in women with dense breast tissue.³ It’s a complex problem that needs a multi-faceted solution.
Syantra DX™ Breast Cancer is a new screening tool for breast cancer that’s effective in detecting cancer in early stages, when outcomes are often better.
Syantra DX™ Breast Cancer is a blood test for breast cancer screening. It’s an easy, convenient, and accurate tool that supports womens’ access to early detection.
How does it work?
Syantra DX™ Breast Cancer is a precision medicine tool that measures a panel of gene expression biomarkers from whole blood. It then uses a software package, developed with machine learning, to interpret data. It provides a molecular approach to breast cancer screening that can detect invasive disease at early stages.
The Syantra DX™ Breast Cancer screening process
An advanced diagnostic protocol
The Syantra DX™ Breast Cancer process involves the collection of a whole blood sample, transportation to a certified clinical laboratory for molecular processing, and result generation through Syantra Inc.’s custom software. A custom laboratory information system has been developed to track samples through the workflow and manage ongoing monitoring of key analytical validation characteristics.
The entire process from sample collection to result generation has been designed, developed and validated to ensure consistency in test outcomes.⁴
The end result indicates whether the sample is
positive or
negative for the signature for breast cancer.
The Syantra DX™ Breast Cancer patient test pathway
Test performance⁴
Syantra DX™ Breast Cancer has been developed over the past decade and has gone through multiple validations, including an ongoing prospective, blinded international study. This study is enrolling women aged 25-80 years around the time of a screening mammogram. Exclusion criteria include previous cancers and breast surgeries in the past year.
Women under 50*
Accuracy
Inferred 98.5% accuracy for women under 50.⁴
Specificity
(ability to detect “no cancer”)
Sensitivity
(ability to detect “cancer”)
Whole cohort: women age 25 to 80 years*
Accuracy
Inferred 92.2% accuracy for women aged 25-80 years .⁴
Specificity
(ability to detect “no cancer”)
Sensitivity
(ability to detect “cancer”)
*Results presented at the San Antonio Breast Cancer Symposium on December 8, 2021 from an interim analysis of IDBC Clinical Study samples from 1,107 participants. Performance metrics are reported for the blind test set with 99.5% confidence intervals (CI) computed through an exact binomial test. There is the potential for false negative and false positive results to occur.
Contact us
Interested in learning more about Syantra DX™ Breast Cancer or Syantra Inc.? Contact us through the form below.
Please note.
Syantra DX™ Breast Cancer is a screening test and may be used as part of the regular screening process. There is the potential for false negative and false positive results to occur. All results should be interpreted by a qualified healthcare provider, and no interventional action should be taken based solely on Syantra DX Breast Cancer results.
Citations.
- SEER Cancer Statistics Review, 1975-2017, 2020.
- DeSantis, C.E. et al., 2019. Breast Cancer Statistics CA: A Cancer Journal for Clinicians. 69: 438.
- Seely et al., 2018. Curr Oncol. June 25 (Suppl 1): S115– S124.
- Syantra DX™ Breast Cancer has been evaluated in clinical studies for women between the ages of 25 and 80. The data infers an accuracy of 92.2% for women between 25 and 80, and 98.5% for women under 50. See IDBC study on clinicaltrials.gov: Bundred, N. et al., A whole blood assay to identify breast cancer: interim analysis of the international identify breast cancer (IDBC) study evidence supporting the Syantra DX Breast Cancer Test, San Antonio Breast Cancer Symposium, 21-A-1625-SABCS, presented December 8, 2021, San Antonio, TX, USA.
